Alnylam Pharma (ALNY) Tops Q3 EPS by 21c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $224.60 -1.77%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.06), $0.21 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $17.1 million versus the consensus estimate of $24.65 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- InspireMD (NSPR) Tops Q2 EPS by 1c
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $256 at Wells Fargo
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
